AT/AF burden, prior antithrombotic therapy and CHA2DS2-VASc Score28 of the 14 patients with AT/AF detected by prolonged Holter monitoring
| Episodes (n) | Cumulative time of AT/AF (min) | Type of arrhythmia | At least 1 episode >6 min | Antithrombotic/ antiplatelet therapy | CHA2DS2-VASc score | |
|---|---|---|---|---|---|---|
| Diast-CHF #2 | 3 | 2 | AT | No | None | 1 |
| Diast-CHF #4 | 1 | 2 | AF | No | ASA | 4 |
| Diast-CHF #5 | 4 | 7 | AT | No | None | 2 |
| Diast-CHF #6 | 1 | 1066 | AF | Yes | ASA | 8 |
| Diast-CHF #7 | 2 | 36 | AT | Yes | ASA | 2 |
| Diast-CHF #8 | 3 | 1160 | AF | Yes | None | 1 |
| Diast-CHF #9 | 2 | 9 | AF | No | None | 1 |
| Diast-CHF #10 | 2 | 13 | AT | Yes | ASA | 5 |
| Find-AF eye #1 | NA | 1 | AF | No | ASA | 2 |
| Find-AF eye #2 | NA | 1 | AF | No | None | 4 |
| Find-AF eye #3 | NA | >1440 | AF | Yes | OAC | 4 |
| Find-AF eye #4 | NA | >1440 | AF | Yes | ASA | 4 |
| Find-AF eye #5 | NA | 989 | AF | Yes | ASA | 4 |
| Find-AF eye #6 | NA | 215 | AF | Yes | ASA | 3 |
AF, atrial fibrillation; ASA, acetylsalicylic acid; AT, atrial tachycardia; CHA2DS2-VASc, congestive heart failure, hypertension, age≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65–74 and sex category (female); NA, not applicable; OAC, oral anticoagulation.